加载中
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
收盘时
US$0.986
−US$0.034 · -3.33%
盘后
US$0.99
+US$0.004 · +0.41%
10月12日 17:38 ET
盘中时间采用ET。市场数据可能有所延迟。
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
日内区间
当前US$0.986
52周区间
当前US$0.986
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
32
偏贵
情绪
45
多空交织
风险
57
风险偏高
动量
40
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
日内区间
当前US$0.986
52周区间
当前US$0.986
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 158万 USD | 968.5万 USD | 757.2万 USD |
| 销货成本 | 169.6万 USD | — | — | — | — |
| 毛利 | −169.6万 USD | — | 158万 USD | 968.5万 USD | 757.2万 USD |
| 研究与开发 | 1.09亿 USD | 1.69亿 USD | 1.28亿 USD | 9693.6万 USD | 7754.9万 USD |
| 销售、一般及管理费用 | 4721.6万 USD | 5905.5万 USD | 5792.8万 USD | 3994.9万 USD | 2755.8万 USD |
| 营业费用 | 1.48亿 USD | 2.28亿 USD | 1.86亿 USD | 1.37亿 USD | 1.05亿 USD |
| 利息收入 | — | 2108.5万 USD | 2407.6万 USD | 467万 USD | 27.2万 USD |
| 利息支出 | 255.9万 USD | 302.4万 USD | 126.7万 USD | 79.1万 USD | — |
| 折旧和摊销 | 169.6万 USD | 212.5万 USD | 184.1万 USD | 182.3万 USD | 153.5万 USD |
| 营业利润 | −1.5亿 USD | −2.28亿 USD | −1.84亿 USD | −1.27亿 USD | −9753.5万 USD |
| 净利润 | −1.49亿 USD | −2.1亿 USD | −1.61亿 USD | −1.23亿 USD | −9726.3万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$25.86
上涨空间 2522.72%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI192.11万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF67.74万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC19.96万0.02%13.17亿 USD0.60%US$181.66-0.73%
Vanguard Health Care ETFVHT17.11万0.00%220亿 USD0.09%US$320.67+0.52%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM8万0.07%1.17亿 USD0.73%US$15.8484-0.58%
Invesco RAFI US 1500 Small-Mid ETFPRFZ2.22万0.00%26.7亿 USD0.36%US$52.92-0.45%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco RAFI US 1500 Small-Mid ETFPRFZAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
